
Newborn screening (NBS) dramatically changed the natural history of GA1, although many patients continue to have devestating symptomes. We aim to understand the post NBS natural history of GA1 including the number of patients who have a basal ganglia injury and non-strital (i.e. non metabolic stroke) symptoms. This data is critial in developing future treatments. This work is funded by NIH (ROAR consoritum) and Alnylam Pharmaceuticals. We also work closely with patient and advocay groups to accomplish these goals.

We focus on the underlying disease mechansim of GA1 and how abnormal metabolism impacts disease phenotype. Our reserach utilizes a zebrafish model which has several advantages to studying this glial cell disorder. We also collaborate with scientist to evalute novel genetic and cellular therapies for GA1 The This work is currently funded internally.

Professor Goodman was a leader in the field of inborn errors of metabolism and founding member of the Society of Inherited Metabolic Disorders. Over his distingused 55 year carreer, his primary focus was glutaric aciduria type 1 and 2. Among other accomplishements, he described the first patient with GA1, identified the gene GCDH, and described the enzyme deficiency in GA1. He developed a mouse model that still used by several laboratories today to study GA1. He was invovled in many clinical studies describing the features of patients with GA1 and the initial guidelines for management.
We are a translational reserch laboratory focused on patient-centered reserach. We combine rigours scientic methods with patient engagement approaches.
Clincical outcomes help prioritze reserch goals and provide critical control data in clincial trials
Collaboration with clinican and scientist advance research and translation of results to the bedside
Partnerships with patients and families to enusre our reserach goals are patient-centered
Animal (zebrafish, mice) and human model systems to interrogate mechansim and novel treatments
Exerpience in genonmics, metaoblimics, proteomics with a focus on disease mechanism
Analytical instrumententaion with a focus on quantiative mass spectrometry approaches
Below are select publications that highlight our work on GA1. Our other mansucripts are avaiable in the publication section of this website and on public databases such as Google Scholar.
Bernstein L, Coughlin CR, Drumm M, Yannicelli S, Rohr F. Inconsistencies in nutritional management of glutaric aciduria type 1: An international survey. Nutrients. 2020 Oct 16;12(10):E3162 Link
Coughlin CR 2nd (2022) Glutaric Aciduria Type I: Diagnosis and Management. In: L Bernstein, F Rohr, S van Calcar (eds). Nutrition Management of Inherited Metabolic Diseases: Lessons from Metabolic University 2nd edition. pp. 277-284. Cham, Switzerland: Springer Nature. Link
Articles highlighed from Dr. Micheal Woontner
Goodman SI, Woontner M. And explanation for metabolite exretion in high- and low-excretor patietns with glutaric acidemia type 1. Mol Genet Metab. 2019 Aug;127(4):325-326 Link
Woontner M, Crini LS, Koeller DM. Analysis of the expression of murine glutaryl-CoA dehydrogenase: in vitro and in vivo studies. Mol Genet Metab. 2000 Feb;69(2):116-22. Link
University of Colorado Anschutz
RC1 North, P18-3401A
Mail stop 8313
Aurora, Colorado 80045